Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Enterprise Value (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Enterprise Value data on record, last reported at -$1.9 billion in Q4 2025.

  • For Q4 2025, Enterprise Value fell 70.69% year-over-year to -$1.9 billion; the TTM value through Dec 2025 reached -$1.9 billion, down 70.69%, while the annual FY2025 figure was -$1.9 billion, 70.69% down from the prior year.
  • Enterprise Value reached -$1.9 billion in Q4 2025 per PTCT's latest filing, down from -$1.7 billion in the prior quarter.
  • Across five years, Enterprise Value topped out at -$286.3 million in Q1 2023 and bottomed at -$2.0 billion in Q1 2025.
  • Average Enterprise Value over 5 years is -$947.3 million, with a median of -$880.8 million recorded in 2023.
  • Peak YoY movement for Enterprise Value: surged 66.77% in 2022, then plummeted 243.73% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$773.4 million in 2021, then skyrocketed by 46.89% to -$410.7 million in 2022, then plummeted by 113.47% to -$876.7 million in 2023, then dropped by 29.99% to -$1.1 billion in 2024, then crashed by 70.69% to -$1.9 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$1.9 billion in Q4 2025, -$1.7 billion in Q3 2025, and -$2.0 billion in Q2 2025.